Leading-Edge Research in Inflammatory Bowel Disease

The UPMC Inflammatory Bowel Disease (IBD) Center specializes in translating research findings into cutting-edge treatments and developing therapeutic strategies for improving patient care.

Treatments for Today, Research for Tomorrow

The past 10 years have been a time of great strides for IBD research and novel therapies.

Today, IBD management requires an understanding of the risks and benefits of new therapies and integration of surgical care, when warranted. The future of IBD management relies on translating laboratory discoveries into clinical care.

Advancing Our Understanding of IBD

Our physician scientists direct several multi-center, international research trials on novel IBD treatments. They are respected authorities in genetics, immunology, and clinical research and their groundbreaking discoveries — such as linking new genes to IBD — have rendered a better understanding of IBD worldwide.

And, more importantly, the research has advanced an individualized approach to care.

While we work toward improving the everyday life of all our patients, finding a cure for IBD is — and always will be — one of our primary goals.

Additional research focus at the UPMC IBD Center includes:

  • An NIDDK/NIH-sponsored, genome-wide association study in IBD that highlights the close pathogenetic relationship between early- and adult-onset IBD.
  • Participation in a national database for patients with IBD that allows investigators to map case similarities in an effort to better understand the disease and formulate proper treatment plans.
  • Phase I to Phase IV clinical pharmaceutical trials testing the effectiveness of new compounds in treating IBD. Many trials have come to fruition and gained FDA approval, becoming standard medications for the treatment of Crohn’s disease and ulcerative colitis.

Contact Us

To schedule an appointment with an IBD subspecialist gastroenterologist, call
412-624-7692. 

To learn more about the UPMC Digestive Disorders Center, call, toll free, 1-866-4GASTRO
(1-866-442-7876).

Additional Resources

Dr. Miguel Reguiero

Dr. Miguel Reguiero discusses the results of a recent 5-year
post-operative study on the efficacy of Infliximab.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com